Seltorexant

Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).[1][2][3] As of December 2015, it is in phase II clinical trials for both insomnia and Major depressive disorder.[2][4][5]

Seltorexant
Clinical data
Other namesMIN-202; JNJ-42847922; JNJ-922
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)

See also

References
  1. Christopher JA (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–38. doi:10.4155/ppa.14.46. PMID 25489915.
  2. Zisapel N (March 2015). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs. 24 (3): 401–11. doi:10.1517/13543784.2015.987340. PMID 25423562.
  3. Boss C, Roch C (August 2015). "Recent trends in orexin research--2010 to 2015". Bioorganic & Medicinal Chemistry Letters. 25 (15): 2875–87. doi:10.1016/j.bmcl.2015.05.012. PMID 26045032.
  4. "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
  5. Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.